ADAPTIVE BIOTECHNOLOGIES CORPORATION Comprehensive Income
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Comprehensive Income of -$39.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$39.97M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.31M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$13.54M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $9.68M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$59.41M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$159.54M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$220.92M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$203.17M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.97M 10-Q · filed 2026-08-04 | -$60.29M 10-Q · filed 2026-08-04 | -$73.82M derived: sum of 3 quarters · filed 2026-08-04 | -$64.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$20.31M 10-Q · filed 2026-05-05 | -$33.85M derived: sum of 2 quarters · filed 2026-05-05 | -$24.17M derived: sum of 3 quarters · filed 2026-05-05 | -$49.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.85M derived: sum of 2 quarters · filed 2026-02-26 | -$29.53M derived: sum of 3 quarters · filed 2026-08-04 | -$59.41M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.68M 10-Q · filed 2025-11-05 | -$15.99M derived: sum of 2 quarters · filed 2026-08-04 | -$45.88M 10-Q · filed 2025-11-05 | -$79.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$25.68M 10-Q · filed 2026-08-04 | -$55.56M 10-Q · filed 2026-08-04 | -$89.58M derived: sum of 3 quarters · filed 2026-08-04 | -$120.97M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$29.88M 10-Q · filed 2026-05-05 | -$63.91M derived: sum of 2 quarters · filed 2026-05-05 | -$95.30M derived: sum of 3 quarters · filed 2026-05-05 | -$141.60M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$34.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$65.42M derived: sum of 2 quarters · filed 2026-02-26 | -$111.71M derived: sum of 3 quarters · filed 2026-02-26 | -$159.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$31.39M 10-Q · filed 2025-11-05 | -$77.69M derived: sum of 2 quarters · filed 2025-11-05 | -$125.52M 10-Q · filed 2025-11-05 | -$194.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$46.30M 10-Q · filed 2025-08-05 | -$94.13M 10-Q · filed 2025-08-05 | -$163.10M derived: sum of 3 quarters · filed 2026-02-26 | -$212.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$47.83M 10-Q · filed 2025-05-01 | -$116.80M derived: sum of 2 quarters · filed 2026-02-26 | -$166.46M derived: sum of 3 quarters · filed 2026-02-26 | -$213.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$68.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$118.63M derived: sum of 2 quarters · filed 2026-02-26 | -$165.43M derived: sum of 3 quarters · filed 2026-02-26 | -$220.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$49.66M 10-Q · filed 2024-11-07 | -$96.45M derived: sum of 2 quarters · filed 2024-11-07 | -$151.94M 10-Q · filed 2024-11-07 | -$190.22M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$46.80M 10-Q · filed 2024-08-01 | -$102.29M 10-Q · filed 2024-08-01 | -$140.56M derived: sum of 3 quarters · filed 2025-03-03 | -$186.01M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$55.49M 10-Q · filed 2024-05-07 | -$93.76M derived: sum of 2 quarters · filed 2025-03-03 | -$139.21M derived: sum of 3 quarters · filed 2025-03-03 | -$192.28M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$38.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$83.72M derived: sum of 2 quarters · filed 2025-03-03 | -$136.79M derived: sum of 3 quarters · filed 2025-03-03 | -$203.17M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$45.45M 10-Q · filed 2023-11-09 | -$98.52M derived: sum of 2 quarters · filed 2023-11-09 | -$164.90M 10-Q · filed 2023-11-09 | -$227.47M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$53.06M 10-Q · filed 2023-08-02 | -$119.44M 10-Q · filed 2023-08-02 | -$182.02M derived: sum of 3 quarters · filed 2024-02-29 | -$238.13M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$66.38M 10-Q · filed 2023-05-03 | -$128.96M derived: sum of 2 quarters · filed 2024-02-29 | -$185.07M derived: sum of 3 quarters · filed 2024-02-29 | -$234.79M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$62.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$118.69M derived: sum of 2 quarters · filed 2024-02-29 | -$168.41M derived: sum of 3 quarters · filed 2024-02-29 | -$209.31M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$56.11M 10-Q · filed 2022-11-03 | -$105.83M derived: sum of 2 quarters · filed 2022-11-03 | -$146.73M 10-Q · filed 2022-11-03 | -$191.84M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$49.72M 10-Q · filed 2022-08-03 | -$90.62M 10-Q · filed 2022-08-03 | -$135.72M derived: sum of 3 quarters · filed 2023-02-14 | -$173.17M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$40.90M 10-Q · filed 2022-05-04 | -$86.01M derived: sum of 2 quarters · filed 2023-02-14 | -$123.45M derived: sum of 3 quarters · filed 2023-02-14 | -$158.15M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$45.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$82.55M derived: sum of 2 quarters · filed 2023-02-14 | -$117.24M derived: sum of 3 quarters · filed 2023-02-14 | -$146.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$37.45M 10-Q · filed 2021-11-03 | -$72.14M derived: sum of 2 quarters · filed 2021-11-03 | -$100.90M 10-Q · filed 2021-11-03 | -$121.41M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$34.70M 10-Q · filed 2021-08-04 | -$63.46M 10-Q · filed 2021-08-04 | -$83.97M derived: sum of 3 quarters · filed 2022-02-15 | -$97.73M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$28.76M 10-Q · filed 2021-05-05 | -$49.27M derived: sum of 2 quarters · filed 2022-02-15 | -$63.03M derived: sum of 3 quarters · filed 2022-02-15 | -$78.40M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$20.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$34.27M derived: sum of 2 quarters · filed 2022-02-15 | -$49.64M derived: sum of 3 quarters · filed 2022-02-15 | -$67.83M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$13.76M 10-Q · filed 2020-11-10 | -$29.13M derived: sum of 2 quarters · filed 2020-11-10 | -$47.32M 10-Q · filed 2020-11-10 | -$60.49M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$15.37M 10-Q · filed 2020-08-10 | -$33.56M 10-Q · filed 2020-08-10 | -$46.73M derived: sum of 3 quarters · filed 2021-02-24 | -$54.99M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$18.19M 10-Q · filed 2020-05-12 | -$31.36M derived: sum of 2 quarters · filed 2021-02-24 | -$39.62M derived: sum of 3 quarters · filed 2021-02-24 | -$52.07M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$13.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$21.43M derived: sum of 2 quarters · filed 2021-02-24 | -$33.88M derived: sum of 3 quarters · filed 2021-02-24 | -$46.39M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$8.25M 10-Q · filed 2019-11-12 | -$20.70M derived: sum of 2 quarters · filed 2019-11-12 | -$33.21M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$12.45M 10-Q · filed 2019-08-13 | -$24.96M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | -$42.91M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |